Karyopharm Therapeutics Unveils Inducement Grants to New Employees Under Nasdaq Regulations
Karyopharm Therapeutics Announced Inducement Grants
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a leading pharmaceutical company dedicated to advancing novel therapies for cancer treatment, made headlines on June 2, 2025, by announcing the granting of restricted stock units (RSUs) to two newly hired employees.
These grants, totaling 566 RSUs, were awarded as part of Karyopharm's 2022 Inducement Stock Incentive Plan, aligning with the Nasdaq Listing Rule 5635(c)(4). This initiative underpins the company's strategic move to enhance its team with top talent crucial for driving its innovative cancer research and therapeutic pipeline.
Details of the RSU Awards
The RSUs awarded carry a three-year vesting schedule, where one-third of the shares will vest on each of the subsequent anniversaries of the grant date, which was May 31, 2025. This gradual vesting approach serves to incentivize the new employees' commitment to Karyopharm and ensures that they remain part of the organization throughout the period.
Additionally, the RSUs come with a provision that, if a
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.